Want to see SE:ICO full AI Analyst Report?

Iconovo AB (ICO) Price & Analysis

1 Followers

ICO Stock Chart & Stats

kr1.03

kr0.03(3.00%)

At close: Jul 31 4:00 PM EDT

kr1.03

kr0.03(3.00%)

Day’s Range― - ―

52-Week Rangekr0.87 - kr2.79

Previous CloseN/A

Volume15.90K

Average Volume (3M)46.24K

Market Cap

kr77.04M

Enterprise Valuekr45.03

Total Cash (Recent Filing)kr49.25M

Total Debt (Recent Filing)kr5.70M

Price to Earnings (P/E)―

Beta-0.32

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.93

Shares Outstanding74,800,380

10 Day Avg. Volume58,575

30 Day Avg. Volume46,237

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.37

Price to Sales (P/S)39.24

P/FCF Ratio-0.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.42

Revenue Forecast (FY)kr29.00M

Bulls Say, Bears Say

Bulls Say

Specialized Inhaler Platform Business ModelIconovo’s core inhaler platforms and device development services create a partner licensing model that scales without large commercial infrastructure. Durable IP and collaboration-based revenue (upfronts, milestones, royalties) support long-term margin leverage if partner projects advance.

Low Leverage And Supportive Balance SheetVery low debt provides financial flexibility to fund development or endure cash burn, reducing near-term refinancing risk. This balance-sheet cushion supports ongoing R&D and partnership work while management pursues licensing and milestone monetization over months.

Recent TTM Revenue ReboundAn 18.8% TTM revenue rebound signals improving partner activity or contract wins, reducing some execution risk. If sustained through continued project progression, this trend can materially de-risk the business model versus prior decline-driven periods.

Bears Say

Persistent Negative ProfitabilityNegative gross profit and heavy operating losses indicate core activities do not yet cover costs, eroding returns and equity over time. Without consistent, sizable partner-derived revenue or margin improvement, profitability will remain a structural constraint on self-sustaining growth.

Negative Operating And Free Cash FlowSustained negative operating and free cash flow forces external funding or dilutive financing, limiting strategic optionality. Ongoing cash burn restricts investment in scale-up, regulatory support or larger manufacturing commitments, raising structural funding risk over months.

Small, Volatile Revenue And Partner DependencyA small, lumpy revenue base driven by partner milestones makes cash flows unpredictable and planning difficult. Long-term success depends on winning and advancing multiple partner projects; single-contract variability creates structural execution risk for sustaining growth and margins.

ICO FAQ

What was Iconovo AB’s price range in the past 12 months?

Iconovo AB lowest stock price was kr0.87 and its highest was kr2.79 in the past 12 months.

What is Iconovo AB’s market cap?

Iconovo AB’s market cap is kr77.04M.

When is Iconovo AB’s upcoming earnings report date?

Iconovo AB’s upcoming earnings report date is Aug 20, 2026 which is in 17 days.

How were Iconovo AB’s earnings last quarter?

Iconovo AB released its earnings results on Apr 24, 2026. The company reported -kr0.105 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.105.

Is Iconovo AB overvalued?

According to Wall Street analysts Iconovo AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Iconovo AB pay dividends?

Iconovo AB does not currently pay dividends.

What is Iconovo AB’s EPS estimate?

Iconovo AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Iconovo AB have?

Iconovo AB has 74,800,380 shares outstanding.

What happened to Iconovo AB’s price movement after its last earnings report?

Iconovo AB reported an EPS of -kr0.105 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.478%.

Which hedge fund is a major shareholder of Iconovo AB?

Currently, no hedge funds are holding shares in SE:ICO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Iconovo AB

Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.